Mechanism of competitive inhibition
The process is based on structural analogy. The inhibitor (I) is very similar in structure to the substrate (S), making it complementary to the binding sites (the so-called anchoring sites) of the active center of the enzyme (E).
Direct competition arises between the substrate and the inhibitor for the same site on the enzyme. Two scenarios are possible:
- Normal reaction: the enzyme interacts with the substrate. An enzyme-substrate complex (ES) is formed, a chemical transformation occurs at the catalytic site, after which reaction products (P) and the free enzyme are released.
- Inhibition: the enzyme binds the inhibitor. As a result, an inactive enzyme-inhibitor complex (EI) is formed. The inhibitor physically blocks substrate access to the catalytic site, and no reaction product is formed.
Features and kinetics
The main distinguishing feature of competitive inhibition is its reversibility. The inhibitor is held in the active site by weak non-covalent bonds and is easily released upon changes in conditions, without permanently destroying or altering the structure of the enzyme.
The effect of the inhibitor directly depends on the substrate concentration. If the substrate concentration is significantly increased, it will displace the inhibitor from the active sites. The probability of forming the functional ES complex will become much higher than that of the inactive EI complex, thereby overcoming the inhibition.
From the perspective of Michaelis–Menten kinetics, this manifests as follows:
- Maximum velocity ($V_{max}$): remains unchanged. At a sufficiently high (excess) amount of substrate, the enzyme still reaches its maximum capacity.
- Michaelis constant ($K_m$): increases. The apparent affinity of the enzyme for the substrate is reduced. To reach half of the maximum reaction velocity, a much higher substrate concentration is now required compared to the absence of the inhibitor.
Equilibrium equations
During competitive inhibition, two competing binding processes occur in the system in parallel:
- Formation of the complex with the substrate and subsequent catalysis:
$E + S \leftrightarrow ES \rightarrow E + P$
- Formation of the dead-end complex with the inhibitor:
$E + I \leftrightarrow EI$
The EI complex is incapable of further transformations and yields no product.
Medical significance
The principles of competitive inhibition are actively used in pharmacology and the treatment of various pathologies.
Treatment of pancreatic diseases In acute pancreatitis and pancreatic necrosis, a dangerous release of the active proteolytic enzyme trypsin into the blood and surrounding tissues occurs. This triggers the process of autodigestion of the organ. To halt this destructive process, patients are administered peptide trypsin inhibitors (e.g., aprotinin, kontrykal, trasylol). By binding to the enzyme, they block its activity.
Use of pseudosubstrates Some competitive inhibitors act as pseudosubstrates (antimetabolites). They occupy the active site, and the enzyme may even carry out the reaction, but ultimately a product with an altered, 'incorrect' structure is synthesized. Such compounds are entirely devoid of normal functional activity. A classic example of this mechanism is the action of sulfonamide antibacterial drugs.
Briefly: answers to topical questions
What substance (substrate) do sulfonamide drugs act as a competitive analogue of?
Sulfonamide drugs are structural analogues of para-aminobenzoic acid (PABA). Acting as competitive inhibitors, they compete with PABA for the active site of enzymes responsible for folic acid synthesis in microorganisms (e.g., dihydropteroate synthase).
- Mechanism of action — by binding to the enzyme, the drugs act as pseudosubstrates, resulting in the formation of a compound that fails to fulfill the functions of folic acid.
- Consequences — due to folic acid deficiency, nucleic acid synthesis is blocked, bacterial cell division becomes impossible, leading to the cessation of their proliferation and death.
What enzyme does malonic acid (malonate) act as a classic competitive inhibitor of?
Malonic acid (malonate) is a classic competitive inhibitor of the enzyme succinate dehydrogenase. This is due to the structural analogy between malonate and the natural substrate of the enzyme, succinate.
- Structural features — both substances contain two carboxyl groups, which ensures structural similarity.
- Mechanism of action — malonate binds to the active site of succinate dehydrogenase via ionic bonds, blocking access for succinate.
- Consequences — the transfer of two hydrogen atoms to the prosthetic group of the enzyme (FAD) becomes impossible, the chemical reaction stops, and the reaction product (fumarate) is not formed.
Class and exam questions
Does the maximum reaction velocity change in competitive inhibition?
No, Vmax does not change. Inhibition can be completely overcome by creating an excess concentration of the substrate.
How does a competitive inhibitor affect the Michaelis constant (Km)?
Km increases. This means that the affinity of the enzyme for the substrate decreases, and a higher substrate concentration is required to reach half of the maximum velocity.
Where does the competitive inhibitor bind?
It binds directly to the active site of the enzyme, competing with the substrate for it.
What else to study on this topic
- Features of non-competitive inhibition
- Mechanisms of irreversible enzyme inhibition
- Structure of the enzyme active site
- Basics of Michaelis–Menten kinetics
- Allosteric regulation of enzymatic activity
Master the entire topic in the "Biochemistry" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on 'Enzyme Competitive Inhibition' and 3,616 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 115 video lessons on the subject
Other topics in the "Enzymology" section
Free video lessons: biochemistryShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.